BPC-157
Also known as: Body Protection Compound-157
Derived from human gastric juice. Animal models suggest effects on angiogenesis, tendon healing and GI repair; human clinical data is very limited.

- Drug class
- Synthetic gastric peptide
- Primary targets
- Multiple pathways (preclinical)
- Dose reference
- No human dosing established
- Half-life
- Not well characterized in humans
- Developer / origin
- Sikiric et al. (academic origin)
- Reference year
- 1991
- Evidence score
- 2/5 - Mostly preclinical evidence
Mostly preclinical evidence
BPC-157 has animal and mechanistic injury-model evidence, but human clinical efficacy and dosing are not established.
Mostly animal, ex vivo, cell, or indirect evidence.
Evidence basis
- Animal injury models
- Narrative/review literature
- FDA safety-risk concerns for compounding
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
BPC-157 guides
Read the matching guide or adjacent research pages for more context.
BPC-157 calculator shortcuts
Open peptide calculators with editable BPC-157 example values already filled in.
Peptide calculators
Use calculators for concentration, unit conversion and repeated-dose accumulation math.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
TB-500
Thymosin Beta-4 fragment
Synthetic fragment of thymosin β4 studied in animal models for cell migration, angiogenesis and tissue repair. No approved human indication.
Thymosin Beta-4
TB4, Tβ4
Thymosin beta-4 sequesters monomeric G-actin to regulate the actin cytoskeleton, enabling cell migration, angiogenesis and tissue repair, with an anti-fibrotic Ac-SDKP fragment.
VIP (Vasoactive Intestinal Peptide)
Aviptadil
VIP activates VPAC1 and VPAC2 receptors, raising intracellular cyclic AMP to drive vasodilation, smooth-muscle relaxation and immune modulation.
Category hub
Open the category page for the full comparison table and FAQ.